Cargando…
Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies
Tardive dyskinesia is a severe motor adverse event of antipsychotic medication, characterized by involuntary athetoid movements of the trunk, limbs, and/or orofacial areas. It affects two to ten patients under long-term administration of antipsychotics that do not subside for years even after the dr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819690/ https://www.ncbi.nlm.nih.gov/pubmed/35140610 http://dx.doi.org/10.3389/fphar.2021.834129 |
_version_ | 1784646102425796608 |
---|---|
author | Tsermpini, Evangelia Eirini Redenšek, Sara Dolžan, Vita |
author_facet | Tsermpini, Evangelia Eirini Redenšek, Sara Dolžan, Vita |
author_sort | Tsermpini, Evangelia Eirini |
collection | PubMed |
description | Tardive dyskinesia is a severe motor adverse event of antipsychotic medication, characterized by involuntary athetoid movements of the trunk, limbs, and/or orofacial areas. It affects two to ten patients under long-term administration of antipsychotics that do not subside for years even after the drug is stopped. Dopamine, serotonin, cannabinoid receptors, oxidative stress, plasticity factors, signaling cascades, as well as CYP isoenzymes and transporters have been associated with tardive dyskinesia (TD) occurrence in terms of genetic variability and metabolic capacity. Besides the factors related to the drug and the dose and patients’ clinical characteristics, a very crucial variable of TD development is individual susceptibility and genetic predisposition. This review summarizes the studies in experimental animal models and clinical studies focusing on the impact of genetic variations on TD occurrence. We identified eight genes emerging from preclinical findings that also reached statistical significance in at least one clinical study. The results of clinical studies are often conflicting and non-conclusive enough to support implementation in clinical practice. |
format | Online Article Text |
id | pubmed-8819690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88196902022-02-08 Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies Tsermpini, Evangelia Eirini Redenšek, Sara Dolžan, Vita Front Pharmacol Pharmacology Tardive dyskinesia is a severe motor adverse event of antipsychotic medication, characterized by involuntary athetoid movements of the trunk, limbs, and/or orofacial areas. It affects two to ten patients under long-term administration of antipsychotics that do not subside for years even after the drug is stopped. Dopamine, serotonin, cannabinoid receptors, oxidative stress, plasticity factors, signaling cascades, as well as CYP isoenzymes and transporters have been associated with tardive dyskinesia (TD) occurrence in terms of genetic variability and metabolic capacity. Besides the factors related to the drug and the dose and patients’ clinical characteristics, a very crucial variable of TD development is individual susceptibility and genetic predisposition. This review summarizes the studies in experimental animal models and clinical studies focusing on the impact of genetic variations on TD occurrence. We identified eight genes emerging from preclinical findings that also reached statistical significance in at least one clinical study. The results of clinical studies are often conflicting and non-conclusive enough to support implementation in clinical practice. Frontiers Media S.A. 2022-01-24 /pmc/articles/PMC8819690/ /pubmed/35140610 http://dx.doi.org/10.3389/fphar.2021.834129 Text en Copyright © 2022 Tsermpini, Redenšek and Dolžan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Tsermpini, Evangelia Eirini Redenšek, Sara Dolžan, Vita Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies |
title | Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies |
title_full | Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies |
title_fullStr | Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies |
title_full_unstemmed | Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies |
title_short | Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies |
title_sort | genetic factors associated with tardive dyskinesia: from pre-clinical models to clinical studies |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819690/ https://www.ncbi.nlm.nih.gov/pubmed/35140610 http://dx.doi.org/10.3389/fphar.2021.834129 |
work_keys_str_mv | AT tsermpinievangeliaeirini geneticfactorsassociatedwithtardivedyskinesiafrompreclinicalmodelstoclinicalstudies AT redenseksara geneticfactorsassociatedwithtardivedyskinesiafrompreclinicalmodelstoclinicalstudies AT dolzanvita geneticfactorsassociatedwithtardivedyskinesiafrompreclinicalmodelstoclinicalstudies |